Display options
Cite
Climent MA, Seguí MA, Peiró G, et al. Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment. Breast. 2001;10(1):67-77doi: 10.1054/brst.2000.0225.
Climent, M. A., Seguí, M. A., Peiró, G., Molina, R., Lerma, E., Ojeda, B., López-López, J. J., & Alonso, C. (2001). Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment. Breast (Edinburgh, Scotland), 10(1), 67-77. https://doi.org/10.1054/brst.2000.0225
Climent, M A, et al. "Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment." Breast (Edinburgh, Scotland) vol. 10,1 (2001): 67-77. doi: https://doi.org/10.1054/brst.2000.0225
Climent MA, Seguí MA, Peiró G, Molina R, Lerma E, Ojeda B, López-López JJ, Alonso C. Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment. Breast. 2001 Feb;10(1):67-77. doi: 10.1054/brst.2000.0225. PMID: 14965564.
Copy Download .nbib Format: NLM
Share it on

Breast. 2001 Feb;10(1):67-77. doi: 10.1054/brst.2000.0225.

Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment.

Breast (Edinburgh, Scotland)

M A Climent, M A Seguí, G Peiró, R Molina, E Lerma, B Ojeda, J J López-López, C Alonso

Affiliations

  1. Instituto Valenciano de Oncología, Barcelona, Spain.

PMID: 14965564 DOI: 10.1054/brst.2000.0225

Abstract

HER-2/neu and p53 expression, conventional clinical and pathologic prognostic factors, were evaluated in a retrospective series of 283 node-positive breast cancer patients. Overexpression was determined by immunohistochemistry in formalin-fixed paraffin-embedded tissue blocks. Twenty one percent were HER-2/neu positive and 40% p53 positive. HER-2/neu expression was related to axillary lymph node metastasis (P=0.014), inflammatory infiltrates (P=0.004), and the absence of oestrogen (ER) (P=0.0026) and progesterone (P=0.01) receptors (PR). p53 expression was related to lymph node involvement (P=0.03), necrosis (P=0.036), absence of ER (P=0.028) and PR (P=0.065). p53 was not associated with outcome. HER-2/neu was an unfavourable prognostic factor for disease-free (DFS) (P=0.05) and overall survival (OS) (P=0.02) in univariate analysis. Multivariate analysis showed that the number of involved axillary nodes (P<0.00001), age (P=0.004), grade (P=0.04), and PR (P=0.04) were independent predictors for OS. ER-positive patients treated with adjuvant tamoxifen had shorter DFS and OS when they were HER-2/neu positive.

Publication Types